Delayed therapeutic hypothermia protects against the myocardial no-reflow phenomenon independently of myocardial infarct size in
Authors:Wangde Dai|||Sharon Hale|||Robert A Kloner
Journal: International journal of cardiology
Publication Type: Journal Article
Date: 2017
DOI: 10.1016/j.ijcard.2017.01.079
ID: 28108128
Affiliations:
Affiliations
HMRI Cardiovascular Research Institute, Huntington Medical Research Institutes, 10 Pico Street, Pasadena, CA 91105, United States; Division of Cardiovascular Medicine of the Keck School of Medicine, University of Southern California, Los Angeles, CA 90017-2395, United States. Electronic address: wangdedai@yahoo.com.|||HMRI Cardiovascular Research Institute, Huntington Medical Research Institutes, 10 Pico Street, Pasadena, CA 91105, United States.|||HMRI Cardiovascular Research Institute, Huntington Medical Research Institutes, 10 Pico Street, Pasadena, CA 91105, United States; Division of Cardiovascular Medicine of the Keck School of Medicine, University of Southern California, Los Angeles, CA 90017-2395, United States.
Abstract
Adjunctive therapies, given in addition to reperfusion to reduce myocardial infarct size, have been disappointing based on clinical trials. New therapeutic targets independent of infarct size modification are needed. The no-reflow phenomenon occurs commonly after the infarct-related coronary artery is opened and predicts poor clinical outcome. We investigated the effects of a single application of delayed (post-reperfusion) therapeutic hypothermia (TH) in a rat model of coronary artery occlusion/reperfusion.
